RWS of Inetetamab HER2 Positive Advanced Breast Cancer

Zhiyong Yu100 enrolled

Overview

This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

HER2-positive Advanced Breast Cancer

Interventions

InetetamabDRUG

8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with stage IV breast cancer 2. Patients with HER2 positive status 3. Patients that received Inetetamab 4. Patients that began Inetetamab therapy prior to June 30, 2021. Exclusion Criteria: Patients treated with an investigational anticancer agent Inetetamab

Outcomes

Primary Outcomes

Progression Free Survival(PFS)

Time frame: 12 months

Incidences of adverse events and toxicities

Time frame: 12 months

Central Contacts

Zhiyong yu

CONTACT

86-13355312277 drzhiyongyu@aliyun.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.